Mr. Stephen Lockyer reports

MEDX ANNOUNCES PROPOSED NON-BROKERED PRIVATE PLACEMENT TO RAISE UP TO $2,500,000 AND STOCK OPTION GRANTS

MedX Health Corp. is proposing to raise up to $2.5-million by way of a non-brokered private placement of up to 35,714,858 units at seven cents per unit. Each unit will comprise one fully paid common share and one share purchase warrant, exercisable to purchase one further common share at the price of nine cents, during the period of one year commencing on the date of issue. Closing of the placement, which may take place in tranches, will be subject to receipt of subscriptions for a minimum of $500,000 and a number of other conditions, including without limitation the receipt of all relevant regulatory and stock exchange approvals or acceptances. It is anticipated that certain Insiders may participate in this placement, though to not more than 25 per cent of the total funds raised. Closing of the placement will be subject to all relevant TSX Venture Exchange or other approvals and compliance with all applicable policies. Qualified agents will receive a cash commission equal to 8 per cent of the gross proceeds received by the company from the sale of the units to subscribers introduced by such agents and agents' warrants equal to 8 per cent of subscriptions introduced by such agents. Each agent's warrant, which will be non-transferable, will entitle the holder to acquire, at the price of seven cents, a unit, comprising one fully paid common share and one non-transferable share purchase warrant, entitling the holder to acquire one additional common share at the price of nine cents. The agents' warrants and any agents' share purchase warrants that may be issued pursuant to the exercise of agents' warrants, if not exercised, will expire one year following the date of issuance.

The company also announces that a total of 9.8 million stock options have been granted pursuant to the company's incentive stock option plan. Grants have been made to directors (750,000 options), officers (one million options), and employees and consultants (8.05 million options). The options are all exercisable at the price of 10 cents per share, are valid for a period of five years and vest immediately, with the exception of 750,000 options granted to a consultant, which will not vest until Dec. 31, 2025. The company notes that a total of 7.12 million previously granted stock options expired unexercised or were forfeited since Jan. 1, 2024. At this time, there is a total of 30 million options available for grant under the company's incentive stock option plan, of which a total of 22.5 million (including the most recent grants) are currently subject to grants, at a weighted average exercise price of 10.2 cents, and 7.5 million remain available for grant under the plan.

About MedX Health Corp.

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its Siascopy on DermSecure telemedicine platform, utilizing its Siascopy technology. Siascopy is also embedded in its products Siametrics, Simsys and MoleMate, which MedX manufactures in its ISO 13485 certified facility. Siametrics, Simsys and MoleMate include hand-held devices that use patented technology utilizing light and its remittance to view up to two millimetres beneath suspicious moles and lesions in a pain-free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration, and Conformite Europeenne for use in Canada, the United States, Australia, New Zealand, the European Union, Brazil and Turkey.

We seek Safe Harbor.